Breaking News, Collaborations & Alliances

Debiopharm Expands Its Radiopharmaceutical Footprint

Exclusive license and research agreement to further develop radioligand program to fight the progression of cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Debiopharm, a Swiss-based biopharma company, has entered into a worldwide, exclusive license and research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further develop their Debio 0228 radioligand program, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. The agreement extends Debiopharm’s radio-oncology portfolio, which currently includes another clinical stage radiotherapeutic and the radiotherapy-enhancing antagonist of IAPs...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters